- Home
- Clinical Trials for Thymic Epithelial Tumors
Clinical Trials for Thymic Epithelial Tumors
Last update: September 29, 2023
Dr. Chul Kim, Georgetown University, Washington, DC, USA
You can also download the entire list as a pdf file.
Active Clinical Trials for Thymic Epithelial Tumors
Abbreviations used: NA=Not applicable, T= Thymoma, TC=Thymic carcinoma
| Type of study | Treatment | Study Title | Disease setting | Phase | Country | NCT | Study contact | Study contact - 2 |
|---|
Type of study | Treatment | Study Title | Disease setting | Phase | Country | NCT | Study contact | Study contact - 2 |
|---|---|---|---|---|---|---|---|---|
| Neoadjuvant treatment | Chemotherapy/toripalimab (anti-PD-1) | Clinical study of neoadjuvant PD-1 antibody (Toripalimab) plus chemotherapy for locally advanced thymic epithelial tumor | Stage III-IVA T and TC | 2 | China | NCT04667793 | NAzhangpeng1121@tongji.edu.cn | |
| Neoadjuvant treatment | Cisplatin/docetaxel/pembrolizumab (anti-PD-1) | neoadjuvant_thymic Epithelial Tumor | Stage III-IVA T and TC | 2 | South Korea | NCT03858582 | keunchil.park@samsung.com | |
| First line systemic treatment for advanced disease | Carboplatin/paclitaxel +/- ramucirumab (VEGFR2 inhibitor) | Carboplatin and paclitaxel with or without ramucirumab in treating patients with locally advanced, recurrent, or metastatic thymic cancer that cannot be removed by surgery. | Treatment naïve advanced TC | 2 | USA | NCT03694002 | astsao@mdanderson.org | |
| First line systemic treatment for advanced disease | Chemotherapy plus pembrolizumab (anti-PD-1) | Single-arm study to carbo-paclitaxel/ nab-paclitaxel combined with pembrolizumab as the first line therapy in treating patients with locally advanced or metastatic invasive thymoma and thymic carcinoma | Advanced T and TC | 4 | China | NCT04554524 | Zhou.yongan@163.com | |
| Second line and beyond systemic treatment for advanced disease | Nivolumab +/- ipilimuab (anti-PD-1/anti-CTLA4) | Nivolumab in patients with type B3 thymoma and thymic Carcinoma (NIVOTHYM) | Type B3 T and TC | 2 | Belgium, France, Netherlands, Spain, Switzerland, UK | NCT03134118 | 1525@eortc.org | |
| Second line and beyond systemic treatment for advanced disease | Avelumab (anti-PD-L1) | A pilot study to investigate the safety and clinical activity of avelumab (MSB0010718C) in thymoma and thymic carcinoma after progression on platinum-based chemotherapy. | Advanced T and TC | 2 | USA | NCT03076554 | shannon.swift@nih.gov | rajana@mail.nih.gov |
| Second line and beyond systemic treatment for advanced disease | Bintrafusp Alfa(bifunctional fusion protein targeting TGF-β and PD-L1) | Bintrafusp Alfa (M7824) in subjects with thymoma and thymic carcinoma | Advanced T and TC | 2 | USA | NCT04417660 | shannon.swift@nih.gov | rajana@mail.nih.gov |
| Second line and beyond systemic treatment for advanced disease | Sunitinib(multi-targeted receptor tyrosine kinase) | Trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines (Style Trial) | Type B3 T and TC | 2 | Italy | NCT03449173 | marina.garassino@istitutotumori.mi.it | rosaria.gallucci@istitutotumori.mi.it |
| Second line and beyond systemic treatment for advanced disease | PT-112(pyrophosphate-platinum conjugate) | PT-112 in subjects with thymoma and thymic carcinoma | Advanced T and TC | 2 | USA | NCT05104736 | shannon.swift@nih.gov | rajana@mail.nih.gov |
| Second line and beyond systemic treatment for advanced disease | KC1036(AXL/ FLT3/VEGFR2 inhibitor) | A study of KC1036 in patients with advanced thymic tumors | Advanced T and TC | 2 | China | NCT05683886 | Wangys75@gmail.com | |
| Second line and beyond systemic treatment for advanced disease | Pembrolizumab(anti-PD-1) | Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer | Advanced T and TC | 1 | USA | NCT03295227 | astsao@mdanderson.org | |
| Second line and beyond systemic treatment for advanced disease | Chemotherapy plus cetuximab(Anti-EGFR antibody) | Chemotherapy plus cetuximab followed by surgical resection in patients with locally advanced or recurrent thymoma or thymic carcinoma. | Stage II-IVA thymoma or thymic carcinoma | 2 | USA | NCT01025089 | NA | |
| Second line and beyond systemic treatment for advanced disease | Pembrolizumab/lenvatinib(anti-PD-1/ multitargeted tyrosine kinase inhibitor) | Combination of pembrolizumab and lenvatinib, in pre-treated thymic carcinoma patients (PECATI) | Type B3 T and TC | 2 | France, Italy, Spain | NCT04710628 | neus.crespo@medsir.org | alicia.garcia@medsir.org |
| Second line and beyond systemic treatment for advanced disease | 177Lu-DOTA-TATE/Olaparib _x000D_(Radiopharmaceutical for PRRT/PARP inhibitor) | 177Lu-DOTA-TATE and olaparib in somatostatin receptor positive tumours (LuPARP) | T among other tumors | 1 | Sweden | NCT04375267 | andreas.hallqvist@vgregion.se | annika.baan@vgregion.se |
| Second line and beyond systemic treatment for advanced disease | Nivolumab/vorolanib (anti-PD-1/multi-kinase VEGF/ PDGFR inhibitor) | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | TC among other thoracic cancers | 1/2 | USA | NCT03583086 | N/A | |
| Second line and beyond systemic treatment for advanced disease | KN046(PD-L1/CTLA-4 bispecific antibody) | KN046 (a humanized PD-L1/CTLA4 bispecific single domain Fc fusion protein antibody) in subjects with thymic carcinoma. | Advanced TC | 2 | China | NCT04469725 | chestgcp@126.com | |
| Second line and beyond systemic treatment for advanced disease | Atezolizumab(Anti-PD-L1) | A study to investigate the efficacy and safety of atezolizumab in previously-treated patients with advanced thymic carcinoma. | Advanced TC | 2 | China | NCT04321330 | NA | |
| Second line and beyond systemic treatment for advanced disease | Pembrolizumab/sunitinib(Anti-PD-1/ multitargeted tyrosine kinase inhibitor) | Pembrolizumab and sunitinib malate in treating participants with refractory metastatic or unresectable thymic cancer | Advanced TC | 2 | USA | NCT03463460 | OSUCCCClinicaltrials@osumc.edu | Carly.Pilcher@osumc.edu |
| Second line and beyond systemic treatment for advanced disease | YY-20394(oral phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor) | A phase 2 clinical study of YY-20394 in patients with relapsed/refractory thymic cancer. | Advanced T and TC | 2 | NA | NCT04975061 | NA | |
| Second line and beyond systemic treatment for advanced disease | VMD-928(TrkA inhibitor) | Selective TrkA inhibitor VMD-928 to treat TrkA overexpression driven solid tumors or lymphoma. | Advanced T and TC among other tumors | 1 | USA | NCT03556228 | OM@VMOncology.com | dadenaike@TD2inc.com |
Showing 1 to 20 of 33 entries